Psilocybin news for Seattle and Washington
The almanac's news desk reports what changes in psilocybin law, research and public health for Seattle, Washington and the Northwest. Every post is dated and lists its sources at the end, primary documents first.
From the shop our team runs, My Mushroom Dispensary. Adults 21+ only.
The desk covers Seattle, Washington and Northwest law and policy (bills, ballot measures, agency rules), new research from Seattle-area institutions and trial sites, public health reports, the licensed psilocybin programs in neighboring Oregon and in Colorado, and anniversaries drawn from the almanac's own timeline and history. Every story carries the date it was published and is reported from primary documents where they exist, such as bill records, statutes, the Federal Register, agency pages and journal articles; where a story relies on news reports or other secondary sources, it names them. When a story changes, we update it and show the new date, as our editorial standards describe. New posts also go out on the RSS feed.
- Washington's 2027 session: no psychedelic bill prefiled yet, and the 2025-26 bills ended in committee
No 2027 bills are prefiled yet; HB 1433, SB 5201, SB 5204 and SB 5921 ended in committee. Session opens January 11.
- UW psilocybin trials reach milestones: cancer retreat study closes at 16, veterans study reaches its estimated data date
The group retreat trial lists 16 enrolled; PsiloStudy's estimated primary completion date, Nov. 1, has passed.
- Usona's Phase 3 psilocybin trial for depression, with Bellevue and Vancouver sites, has no results yet
uAspire enrolled 238 people and finished primary data collection January 5; no results were public as of Nov. 2.
- Fifty years ago, a Washington mushroom meeting put Wasson, Guzmán, Ott and Stamets on one program
In 1976, about 120 people met at a Washington state park to hear Wasson, Guzmán, Ott and Stamets.
- Psilocybe stuntzii at 50: the species named for UW botanist Daniel Stuntz
Described in Mycologia's November to December 1976 issue, the species honors UW botanist Daniel E. Stuntz.
- Oregon drafts new psilocybin client rules after dropping fee increases
Committee meetings Nov. 2 and 4 on consent and client rights drafts; advisory board meets Nov. 6.
- Reedsport and Redmond, Oregon, vote November 3 on keeping psilocybin businesses out
Two Oregon cities vote November 3 on psilocybin businesses: a ban in Reedsport and, as reported, a Redmond moratorium.
- Idaho votes November 3 on HJR 4, which would leave drug legalization to the Legislature
Idaho's November 3 ballot asks whether only the Legislature may legalize marijuana and other psychoactive substances.
- FDA asks how ibogaine trials should be run, with comments due November 20; Washington's ibogaine bill stayed in committee
FDA's request covers care setting, heart monitoring and stopping rules; Washington's SB 5204 stayed in committee.
- Definium says its LSD drug met its goal in a second anxiety Phase 3, the drug's third positive Phase 3, with Washington sites in the program
Panorama, with an Everett site, met its main goal; Seattle and Vancouver, WA sites appear in two other trials.
- DEA's five-tryptamine proposal: comments closed with 267 posted, and no hearing notice yet
Comments closed October 23 on DEA's plan to put five tryptamines in Schedule I; 267 are posted and no hearing is set.
- Colorado holds its final hearing on natural medicine rules as August emergency rules near their limit
Nov. 4 hearing on HB26-1325 rules; emergency rules on limited sales licenses last up to 120 days after adoption.
Follow along with the RSS feed.